We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Report: FDA Has Spent $65.9 Million on Biosimilars Work
Report: FDA Has Spent $65.9 Million on Biosimilars Work
An interim report shows that the FDA has conducted nearly 90 meetings with more than 50 drug companies interested in producing biosimilar products since 2013 at a cost of $65.9 million.